RIGLRigel Pharmaceuticals, Inc.
$48.76+65% 1Y
$48.76
$25.4452 weeks$50.96
The financials
Rigel Pharmaceuticals, Inc. by the numbers
Rigel Pharmaceuticals, Inc. (RIGL) reported revenue of $79M in Q2 2026 (quarter ended Jun 30, 2026), down 23% from the same quarter a year earlier. That came with a gross margin of 89% and net income of $17M (22% of revenue). For the full year FY2025, revenue was $294M (+64% year on year) and net income $367M. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $79M | $102M | −23% |
| Gross profit | $70M | $97M | −28% |
| Operating income | $24M | $61M | −61% |
| Net income | $17M | $60M | −71% |
| Diluted EPS | $0.88 | $3.28 | −73% |